Company · JNJ
Johnson & Johnson (Janssen)
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
131
60 still marketed
Novel approvals
51
Approvals since 2021
77
Originals and new uses
Phase 3 trials
282
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Rybrevant Faspro new use Priority reviewNov 5, 2026
- Stelara new use OrphanAug 28, 2026
- Imaavy new use Priority reviewOrphanAug 24, 2026
- Tremfya new use May 28, 2026
- Uptravi new use Priority reviewOrphanMay 23, 2026
- Stelara new use OrphanApr 15, 2026
- Icotyde approved NovelPriority reviewMar 17, 2026
- Tecvayli new use Breakthrough therapyPriority reviewOrphanMar 5, 2026
- Prezcobix new use Feb 27, 2026
- Prezcobix approved Feb 27, 2026
Drugs in development (23)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- GlucocorticoidsPhase 37 trials
Novartis · VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- TAR-200JNJ-17000139, Gemcitabine-Releasing Intravesical SystemPhase 35 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Bladder Cancer
- JNJ-78934804JNJ-4804Phase 34 trials
Johnson & Johnson (Janssen) · Colitis, Ulcerative, Crohn's Disease, Crohn Disease
- PasritamigJNJ-78278343Phase 34 trials
Johnson & Johnson (Janssen) · Solid Tumor, Metastatic Castration-resistant Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- MilvexianJNJ-70033093, BMS-986177Phase 33 trials
Johnson & Johnson (Janssen) · Ischemic Stroke; Ischemic Attack, Transient, Atrial Fibrillation, Acute Coronary Syndrome
- VinflunineJavlorPhase 33 trials
Merck & Co. · Bladder Cancer, Urothelial Cancer, Locally Advanced or Metastatic Unresectable Urothelial Cancer
- BleximenibJNJ-75276617Phase 32 trials
Johnson & Johnson (Janssen) · Acute Leukemia, Leukemia, Myeloid, Acute
- JNJ-101556143Phase 32 trials
Johnson & Johnson (Janssen) · Prostatic Neoplasms
- JNJ-81201887AAVCAGsCD59Phase 32 trials
Johnson & Johnson (Janssen) · Geographic Atrophy, Macular Degeneration
- JNJ-90301900NBTXR3, Functionalized hafnium oxide nanoparticlesPhase 32 trials
Johnson & Johnson (Janssen) · Carcinoma, Squamous Cell, Carcinoma, Non-Small-Cell Lung
- SeltorexantJNJ 42847922Phase 32 trials
Johnson & Johnson (Janssen) · Depressive Disorder, Major
- JNJ-87189401Phase 31 trial
Johnson & Johnson (Janssen) · Metastatic Castration-resistant Prostatic Neoplasms
- New of NiraparibPhase 31 trial
Johnson & Johnson (Janssen) · Castration-Resistant Prostatic Cancer
- JNJ-95597528Phase 22 trials
Johnson & Johnson (Janssen) · Dermatitis, Atopic, Asthma
- JNJ-64042056Phase 21 trial
Johnson & Johnson (Janssen) · Alzheimer Disease
- JNJ-88545223Phase 21 trial
Johnson & Johnson (Janssen) · Arthritis, Psoriatic
- JNJ-89495120Phase 21 trial
Johnson & Johnson (Janssen) · Depressive Disorder, Major
- JNJ-90014496Phase 21 trial
Johnson & Johnson (Janssen) · Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
- PIPE-307Phase 21 trial
Johnson & Johnson (Janssen) · Relapsing Remitting Multiple Sclerosis
Recruiting Phase 3 trials
Largest first.
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05552222 · 1,590 participants (planned) · Start Oct 25, 2022 · Primary completion Apr 30, 2031
Drug: Teclistamab; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Gilbert, Arizona; Tucson, Arizona; Clovis, California · 270 sites in all
- A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)Pivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07164443 · 1,203 participants (planned) · Start Sep 2, 2025 · Primary completion Aug 18, 2028
Drug: Pasritamig; Best Supportive Care (BSC) and 1 more · For: Metastatic Castration-resistant Prostatic Neoplasms
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 176 sites in all
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07196722 · 1,092 participants (planned) · Start Oct 3, 2025 · Primary completion Sep 19, 2028
Drug: Icotrokinra; Placebo · For: Crohn Disease
Sites: Chandler, Arizona; Litchfield Park, Arizona; Scottsdale, Arizona · 395 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07665450 · 1,000 participants (planned) · Start Sep 9, 2026 · Primary completion Sep 4, 2030
Drug: Ramantamig; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Darlinghurst, Australia; South Brisbane, Australia; Brno, Czechia · 103 sites in all
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06662786 · 1,000 participants (planned) · Start Oct 18, 2024 · Primary completion Dec 15, 2028
Drug: Amivantamab; Cetuximab and 4 more · For: Colorectal Neoplasms
Sites: Gilbert, Arizona; Jonesboro, Arkansas; Springdale, Arkansas · 239 sites in all
- A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate CancerPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07225946 · 800 participants (planned) · Start Dec 19, 2025 · Primary completion Nov 19, 2027
Drug: Pasritamig; Docetaxel and 1 more · For: Prostatic Neoplasms, Castration-Resistant
Sites: Chandler, Arizona; Little Rock, Arkansas; Springdale, Arkansas · 165 sites in all
- Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06559306 · 752 participants (planned) · Start Jul 25, 2024 · Primary completion Dec 30, 2026
Drug: Seltorexant; Placebo and 1 more · For: Depressive Disorder, Major
Sites: Birmingham, Alabama; Chandler, Arizona; Tucson, Arizona · 205 sites in all
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07518186 · 700 participants (planned) · Start May 31, 2026 · Primary completion Apr 29, 2029
Drug: JNJ-79635322; Teclistamab · For: Multiple Myeloma
Sites: Birmingham, Alabama; Phoenix, Arizona; Springdale, Arkansas · 173 sites in all
- A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06750094 · 700 participants (planned) · Start Dec 12, 2024 · Primary completion Dec 15, 2027
Drug: Amivantamab; Cetuximab and 4 more · For: Colorectal Neoplasms
Sites: Chandler, Arizona; Gilbert, Arizona; Prescott, Arizona · 251 sites in all
- A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07577856 · 644 participants (planned) · Start May 23, 2026 · Primary completion Aug 11, 2028
Drug: JNJ-78934804; Guselkumab · For: Colitis, Ulcerative
Sites: Scottsdale, Arizona; Sun City, Arizona; Anaheim, California · 318 sites in all
Marketed drugs (60)
Newest FDA action first.
- Lazcluze Lazertinib Mesylate · 2024
- Rybrevant Faspro Amivantamab and Hyaluronidase-Lpuj · 2025
- Tracleer Bosentan · 2001
- Tracleer Bosentan · 2017
- Spravato Esketamine Hydrochloride · 2019
- Stelara Ustekinumab · 2009
- Stelara Ustekinumab · 2016
- Imaavy Nipocalimab-Aahu · 2025
- Invokamet Canagliflozin, Metformin Hydrochloride · 2014
- Invokamet Xr Canagliflozin, Metformin Hydrochloride · 2016
- Sporanox Itraconazole · 1992
- Erleada Apalutamide · 2018
- Invokana Canagliflozin · 2013
- Tremfya Guselkumab · 2017
- Darzalex Daratumumab · 2015
- Uptravi Selexipag · 2015
- Uptravi Selexipag · 2021
- Tecvayli Teclistamab-Cqyv · 2022
- Talvey Talquetamab-Tgvs · 2023
- Concerta Methylphenidate Hydrochloride · 2000
- Xarelto Rivaroxaban · 2011
- Icotyde Icotrokinra Hydrochloride · 2026
- Topamax Topiramate · 1996
- Topamax Sprinkle Topiramate · 1998
- Prezcobix Cobicistat, Darunavir Ethanolate · 2015
- Prezcobix Darunavir and Cobicistat, Cobicistat, Darunavir Ethanolate · 2026
- Rybrevant Faspro Amivantamab and Hyaluronidase-Lpuj · 2026
- Darzalex Faspro Daratumumab and Hyaluronidase-Fihj · 2020
- Yondelis Trabectedin · 2015
- Akeega Abiraterone Acetate, Niraparib Tosylate · 2023
- Rybrevant Amivantamab-Vmjw · 2021
- Simponi Golimumab · 2009
- Balversa Erdafitinib · 2019
- Inlexzo Gemcitabine Hydrochloride · 2025
- Sirturo Bedaquiline Fumarate · 2012
- Simponi Aria Golimumab · 2013
- Opsynvi Macitentan, Tadalafil · 2024
- Opsumit Macitentan · 2013
- Remicade Infliximab · 1998
- Invega Sustenna Paliperidone Palmitate · 2009
- Invega Hafyera Paliperidone Palmitate · 2015
- Invega Paliperidone · 2006
- Risperdal Risperidone · 1996
- Risperdal Consta Risperidone · 2003
- Risperdal Risperidone · 1993
- Edurant Rilpivirine Hydrochloride · 2011
- Edurant Ped Rilpivirine Hydrochloride · 2024
- Symtuza Cobicistat, Darunavir, Emtricitabine, Tenofovir Alafenamide Fumarate · 2018
- Prezista Darunavir · 2006
- Prezista Darunavir · 2011
- Xarelto Rivaroxaban · 2011
- Zytiga Abiraterone Acetate · 2011
- Elmiron Pentosan Polysulfate Sodium · 1996
- Zavesca Miglustat · 2003
- Veletri Epoprostenol Sodium · 2008
- Reopro Abciximab · 1994
- Intelence Etravirine · 2008
- Ortho Tri-Cyclen 28 Ethinyl Estradiol, Norgestimate · 2005
- Invega Paliperidone · 2007
- Sporanox Itraconazole · 1996
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.